These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 30444202)
1. Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation. Caroleo B; Caroleo MC; Cimellaro A; Colangelo L; Perticone M; Di Mizio G; De Sarro G; Gallelli L Curr Drug Saf; 2019; 14(1):67-71. PubMed ID: 30444202 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience. Ueda Y; Kobayashi T; Ikegami T; Miuma S; Mizuno S; Akamatsu N; Takaki A; Ishigami M; Takatsuki M; Sugawara Y; Maehara Y; Uemoto S; Seno H J Gastroenterol; 2019 Jul; 54(7):660-666. PubMed ID: 30806783 [TBL] [Abstract][Full Text] [Related]
3. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293 [TBL] [Abstract][Full Text] [Related]
4. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879 [TBL] [Abstract][Full Text] [Related]
5. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494 [TBL] [Abstract][Full Text] [Related]
6. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E; J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ Int J Drug Policy; 2019 Apr; 66():73-79. PubMed ID: 30735896 [TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. Lampertico P; Carrión JA; Curry M; Turnes J; Cornberg M; Negro F; Brown A; Persico M; Wick N; Porcalla A; Pangerl A; Crown E; Larsen L; Yu Y; Wedemeyer H J Hepatol; 2020 Jun; 72(6):1112-1121. PubMed ID: 32061651 [TBL] [Abstract][Full Text] [Related]
9. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older. Huff J; Andersen R Ann Pharmacother; 2020 Mar; 54(3):262-276. PubMed ID: 31537106 [No Abstract] [Full Text] [Related]
10. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228 [TBL] [Abstract][Full Text] [Related]
11. A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis. Yoon JH; Kim SM; Kang G; Kim HJ; Jun CH; Choi SK Medicine (Baltimore); 2019 Sep; 98(39):e17343. PubMed ID: 31574875 [TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. D'Ambrosio R; Pasulo L; Puoti M; Vinci M; Schiavini M; Lazzaroni S; Soria A; Gatti F; Menzaghi B; Aghemo A; Capelli F; Rumi MG; Morini L; Giorgini A; Pigozzi MG; Rossini A; Maggiolo F; Pan A; Memoli M; Spinelli O; Del Poggio P; Saladino V; Spinetti A; De Bona A; Capretti A; Uberti-Foppa C; Bonfanti P; Terreni N; Menozzi F; Colombo AE; Giglio O; Centenaro R; Borghi M; Baiguera C; Picciotto V; Landonio S; Gori A; Magnani C; Noventa F; Paolucci S; Lampertico P; Fagiuoli S; J Hepatol; 2019 Mar; 70(3):379-387. PubMed ID: 30472321 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Asselah T; Lee SS; Yao BB; Nguyen T; Wong F; Mahomed A; Lim SG; Abergel A; Sasadeusz J; Gane E; Zadeikis N; Schnell G; Zhang Z; Porcalla A; Mensa FJ; Nguyen K Lancet Gastroenterol Hepatol; 2019 Jan; 4(1):45-51. PubMed ID: 30393106 [TBL] [Abstract][Full Text] [Related]
14. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. Zeuzem S; Foster GR; Wang S; Asatryan A; Gane E; Feld JJ; Asselah T; Bourlière M; Ruane PJ; Wedemeyer H; Pol S; Flisiak R; Poordad F; Chuang WL; Stedman CA; Flamm S; Kwo P; Dore GJ; Sepulveda-Arzola G; Roberts SK; Soto-Malave R; Kaita K; Puoti M; Vierling J; Tam E; Vargas HE; Bruck R; Fuster F; Paik SW; Felizarta F; Kort J; Fu B; Liu R; Ng TI; Pilot-Matias T; Lin CW; Trinh R; Mensa FJ N Engl J Med; 2018 Jan; 378(4):354-369. PubMed ID: 29365309 [TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection. Flamm S; Reddy KR; Zadeikis N; Hassanein T; Bacon BR; Maieron A; Zeuzem S; Bourliere M; Calleja JL; Kosloski MP; Oberoi RK; Lin CW; Yu Y; Lovell S; Semizarov D; Mensa FJ Clin Gastroenterol Hepatol; 2019 Feb; 17(3):527-535.e6. PubMed ID: 30012435 [TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Atsukawa M; Tsubota A; Toyoda H; Takaguchi K; Nakamuta M; Watanabe T; Michitaka K; Ikegami T; Nozaki A; Uojima H; Fukunishi S; Genda T; Abe H; Hotta N; Tsuji K; Ogawa C; Tachi Y; Shima T; Shimada N; Kondo C; Akahane T; Aizawa Y; Tanaka Y; Kumada T; Iwakiri K Aliment Pharmacol Ther; 2019 May; 49(9):1230-1241. PubMed ID: 30873651 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment. Kosloski MP; Wang H; Pugatch D; Mensa FJ; Gane E; Lawitz E; Marbury TC; Preston RA; Kort J; Liu W Eur J Clin Pharmacol; 2019 Feb; 75(2):217-226. PubMed ID: 30341499 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. Suda G; Hasebe C; Abe M; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Haga H; Ueno Y; Abe K; Takahashi A; Ohira H; Tsukuda Y; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Inoue J; Terasita K; Ohara M; Kawagishi N; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N; J Gastroenterol; 2019 Jul; 54(7):641-649. PubMed ID: 30778716 [TBL] [Abstract][Full Text] [Related]
20. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]